Last $216.03 USD
Change Today +2.27 / 1.06%
Volume 454.2K
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Riverwalk

Citywest Business Campus

Dublin, 24

Ireland

Phone: 353 1 429 7700

Fax:

The company plans to file for FDA regulatory approval of VYVANSE for the treatment of BED in adults (ages 18 to 55) by the third quarter of 2014. INTUNIV for the treatment of ADHD in the EU INTUNIV for the treatment of ADHD in children aged 6 to 17 in the EU was initiated in 2011 and has been completed. INTUNIV for the treatment of ADHD in Japan: Under a collaboration agreement, Shionogi and the company would co-develop and sell ADHD products in Japan, including INTUNIV. A Phase 3 clinical program to evaluate the efficacy and safety of INTUNIV in Japanese patients aged 6 to 17 was initiated in 2013. SHP606 Lifitegrast for the Treatment of Dry Eye Disease: A Phase 3 clinical program to further assess the efficacy of SHP606 for the treatment of Dry Eye disease was initiated in the United States in 2012 and top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5.0% Lifitegrast ophthalmic solution, were announced in 2013. SHP555 (prucalopride; marketed as RESOLOR in the EU) for the treatment of chronic constipation in the United States: In 2012, the company announced that it had acquired the rights to develop and market prucalopride in the United States in an agreement with Janssen Pharmaceutica N.V. Discussions are planned with the FDA to determine potential clinical development pathways. FIRAZYR for the treatment of ACE-I AE: A Phase 3 clinical trial to assess the efficacy of FIRAZYR for the treatment of ACE-I AE was initiated in 2013 and is ongoing. SHP609 for the treatment of Hunter syndrome with CNS symptoms: SHP609 is in development as an enzyme replacement therapy (ERT) delivered intrathecally for Hunter syndrome patients with CNS symptoms. The company initiated a pivotal Phase 2/3 clinical trial in 2013 which is ongoing. This product has been granted orphan designation in the United States. Phase 2 LDX for the treatment of ADHD in Japan: Under a collaboration agreement, Shionogi and the company would co-develop and sell ADHD products in Japan, including LDX. A Phase 2 clinical program to evaluate the efficacy and safety of LDX in Japanese patients aged 6 to 17 was initiated in the second quarter of 2013 and is ongoing. SHP602 Iron Chelating Agent for the Treatment Of Iron Overload Secondary to Chronic Transfusion: A Phase 2 trial in pediatric and adult patients with transfusional iron overload is ongoing. This product has received orphan drug designation by the EMA and the FDA for the treatment of chronic iron overload requiring chelation therapy. SHP610 for Sanfilippo A Syndrome (Mucopolysaccharidosis IIIA): SHP610 is in development as an ERT delivered intrathecally for the treatment of Sanfilippo A Syndrome, a Lysosomal Storage Disorder (LSD). The company initiated a Phase 1/2 clinical trial in 2010 which has completed. The company is planning the next clinical trial for SHP610, designed to measure a clinical response, which is expected to initiate in 2014. The product has been granted orphan drug designation in the United States and in the EU. SHP613 for the treatment of improvement in patency of arteriovenous (AV) access in hemodialysis patients: SHP613 is an endothelial cell based therapy in development for enhancing blood vessel repair and improving hemodialysis access for patients with end-stage renal disease (ESRD). This product has been granted orphan drug designation in the United States and the EU. In 2013, the company enrolled the first patients in its two Phase 2 studies designed to evaluate the efficacy and safety of SHP613 in improving AV Fistula (AVF) maturation and AV Graft (AVG) patency to facilitate hemodialysis in patients with ESRD. SHP607 for the treatment of Retinopathy of Prematurity (ROP): SHP607 is in development as a protein replacement therapy for the preventative treatment of ROP, a rare eye disorder associated with premature birth. This product has been granted orphan drug designation both in the United States and EU. A Phase 2 clinical trial is ongoing. Phase 1 SHP611 for the treatment of Metachromatic Leukodystrophy (MLD): SHP611 is in development as an ERT delivered intrathecally for the treatment of the late infantile form o

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $216.03 USD +2.27

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $224.17 USD +1.38
Astellas Pharma Inc ¥1,784 JPY -33.00
CSL Ltd A$85.35 AUD +0.91
Mylan Inc/PA $54.21 USD -0.23
Valeant Pharmaceuticals International Inc C$198.25 CAD +0.85
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 23.2x
Price/Sales 7.3x
Price/Book 6.5x
Price/Cash Flow 32.8x
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.